Successful treatment of acute myelomonocytic leukaemia with NUP98-HOXD11 fusion transcripts and monitoring of minimal residual disease.
Patients with haematological malignancies involving the NUP98 gene have been reported to have an aggressive clinical course and a poor outcome. We report successful treatment of a 15-year-old Japanese boy with acute myelomonocytic leukaemia having t(2;11)(q31;p15) and a novel fusion transcript, NUP98-HOXD11. He achieved complete remission by combined chemotherapy, and underwent unrelated cord blood transplantation 4 months after diagnosis. He is in complete remission 24 months after diagnosis. Monitoring of minimal residual disease (MRD) showed the absence of fusion transcript 12 months after transplantation. This is the first report of monitoring MRD in a patient with haematological malignancy involving NUP98 fusion transcripts.
Terui
Kiminori
K
Department of Paediatrics, Hirosaki University School of Medicine, Aomori, Japan.
Kitazawa
Junichi
J
Takahashi
Yoshihiro
Y
Tohno
Chikako
C
Hayashi
Yasuhide
Y
Taketani
Takeshi
T
Taki
Tomohiko
T
Ito
Etsuro
E
D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002880:Chromosomes, Human, Pair 11; D002889:Chromosomes, Human, Pair 2; D003131:Combined Modality Therapy; D036101:Cord Blood Stem Cell Transplantation; D015321:Gene Rearrangement; D006801:Humans; D007621:Karyotyping; D015479:Leukemia, Myelomonocytic, Acute / Q000188:drug therapy / Q000235:genetics* / Q000601:surgery; D008297:Male; D018365:Neoplasm, Residual; D015514:Oncogene Proteins, Fusion / Q000235:genetics*; D020133:Reverse Transcriptase Polymerase Chain Reaction
C472321:NUP98-HOXD11 fusion oncogene protein, human; D015514:Oncogene Proteins, Fusion